Cencora, Inc. (NYSE: COR), a global pharmaceutical solutions organization with a market capitalization of $43.4 billion, has completed the acquisition of Retina Consultants of America (RCA), a management services organization of retina specialists. With the closure of this deal, Cencora has revised its fiscal year 2025 adjusted earnings per share (EPS) guidance upwards.
The transaction, which was finalized for a cash outlay of $4.4 billion after adjustments, sees Cencora acquiring an 85% stake in RCA, with the remaining equity held by certain RCA physicians and management members. This strategic move aims to enhance Cencora's position in specialty medical services and to extend its management services organization (MSO) solutions, thereby delivering increased value to stakeholders including physicians and patients.
In light of the acquisition, Cencora's financial guidance for the fiscal year 2025 has been updated to reflect RCA's expected contribution and continued momentum within Cencora's U.S. Healthcare Solutions segment. The company now anticipates an adjusted diluted EPS in the range of $15.15 to $15.45, up from the previously estimated range of $14.80 to $15.10. According to InvestingPro analysis, Cencora appears undervalued at its current trading price of $224.74, with 14 additional exclusive insights available to subscribers.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.